Document Detail


Significance of plasma osteopontin levels in patients with bladder urothelial carcinomas.
MedLine Citation:
PMID:  23055388     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND OBJECTIVE: Previous studies have suggested that the plasma level of osteopontin may be a biomarker for cancer metastases and clinical prognosis; however, its role in bladder urothelial carcinoma (BUC) remains unknown. The purpose of this study was to explore the significance of plasma osteopontin levels in evaluating the pathologic features of BUC and its potential as a prognostic marker in BUC patients.
METHODS: A total of 225 patients with BUC were enrolled in this study, and 230 age-matched and sex-matched healthy volunteers were enrolled as control subjects. The histologic classification of BUC, clinical stage of the disease, and plasma osteopontin levels were determined at admission. Patients with non-muscle-invasive BUC underwent transurethral resection, while those with muscle-invasive BUC underwent radical cystectomy. Patients receiving transurethral resection and radical cystectomy were followed up to determine their tumor-free interval and overall survival, respectively.
RESULTS: The mean plasma osteopontin levels were significantly higher in BUC patients than in controls, significantly higher in patients with high-grade BUC than in those with low-grade BUC, and significantly higher in patients with muscle-invasive BUC than in those with non-muscle-invasive BUC. Patients with bladder-confined disease had the lowest osteopontin levels, while those with lymph node-positive disease had higher osteopontin levels, and those with metastatic BUC had the highest osteopontin expression. Kaplan-Meier analyses showed that a higher plasma osteopontin level was associated with a lower overall survival rate in muscle-invasive BUC patients receiving radical cystectomy.
CONCLUSION: Our results show that the plasma osteopontin level is associated with the clinical features of BUC and predicts the prognosis of muscle-invasive BUC in patients receiving radical cystectomy.
Authors:
Li Zhao; Yalin Wang; Nan Qu; Chen Huang; Lijun Chen
Related Documents :
23601218 - Phosphorylated mammalian target of rapamycin is associated with an adverse outcome in o...
24515658 - Impact of vascular endothelial growth factor expression on overall survival in patients...
3084058 - Radiation therapy for nasopharyngeal carcinoma. retrospective review of 105 patients ba...
12833458 - Treatment outcome after radiotherapy alone for patients with stage i-ii nasopharyngeal ...
7911158 - High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous ...
23683828 - Multidose stereotactic radiosurgery (9 gy × 3) of the postoperative resection cavity f...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Molecular diagnosis & therapy     Volume:  16     ISSN:  1179-2000     ISO Abbreviation:  Mol Diagn Ther     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-19     Completed Date:  2013-03-28     Revised Date:  2013-05-16    
Medline Journal Info:
Nlm Unique ID:  101264260     Medline TA:  Mol Diagn Ther     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  311-6     Citation Subset:  IM    
Affiliation:
Department of Urology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Carcinoma, Transitional Cell / blood*,  pathology,  surgery
Case-Control Studies
Cystectomy
Disease Progression
Enzyme-Linked Immunosorbent Assay
Female
Humans
Kaplan-Meier Estimate
Logistic Models
Male
Middle Aged
Multivariate Analysis
Osteopontin / blood*,  isolation & purification
Prognosis
Survival Rate
Urinary Bladder / pathology,  surgery
Urinary Bladder Neoplasms / blood*,  pathology,  surgery
Chemical
Reg. No./Substance:
106441-73-0/Osteopontin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Two-dimensional J-resolved proton MR spectroscopy and prior knowledge fitting (ProFit) in the fronta...
Next Document:  Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic ...